It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCRX’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCRX’s TA Score shows that 3 TA indicator(s) are bullish while TEVA’s TA Score has 2 bullish TA indicator(s).
PCRX (@Pharmaceuticals: Other) experienced а -7.51% price change this week, while TEVA (@Pharmaceuticals: Other) price change was -4.29% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +56.20%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -6.95%.
PCRX is expected to report earnings on Feb 27, 2025.
TEVA is expected to report earnings on Feb 05, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
PCRX | TEVA | PCRX / TEVA | |
Capitalization | 1.36B | 15.1B | 9% |
EBITDA | 155M | 1.56B | 10% |
Gain YTD | -51.245 | 62.261 | -82% |
P/E Ratio | 32.74 | 22.62 | 145% |
Revenue | 675M | 15.8B | 4% |
Total Cash | 279M | 3.23B | 9% |
Total Debt | 586M | 20.2B | 3% |
PCRX | TEVA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 25 | |
SMR RATING 1..100 | 83 | 92 | |
PRICE GROWTH RATING 1..100 | 59 | 46 | |
P/E GROWTH RATING 1..100 | 100 | 18 | |
SEASONALITY SCORE 1..100 | 10 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCRX's Valuation (56) in the Pharmaceuticals Other industry is in the same range as TEVA (82) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's Profit vs Risk Rating (25) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.
PCRX's SMR Rating (83) in the Pharmaceuticals Other industry is in the same range as TEVA (92) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's Price Growth Rating (46) in the Pharmaceuticals Generic industry is in the same range as PCRX (59) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to PCRX’s over the last 12 months.
TEVA's P/E Growth Rating (18) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.
PCRX | TEVA | |
---|---|---|
RSI ODDS (%) | 3 days ago81% | N/A |
Stochastic ODDS (%) | 3 days ago74% | 3 days ago75% |
Momentum ODDS (%) | 3 days ago85% | 3 days ago77% |
MACD ODDS (%) | 3 days ago84% | 3 days ago80% |
TrendWeek ODDS (%) | 3 days ago78% | 3 days ago67% |
TrendMonth ODDS (%) | 3 days ago68% | 3 days ago65% |
Advances ODDS (%) | 9 days ago0% | N/A |
Declines ODDS (%) | 3 days ago78% | 3 days ago73% |
BollingerBands ODDS (%) | 3 days ago81% | 3 days ago82% |
Aroon ODDS (%) | 3 days ago71% | 3 days ago79% |
A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.
Ticker / NAME | Correlation To PCRX | 1D Price Change % | ||
---|---|---|---|---|
PCRX | 100% | -2.08% | ||
ELAN - PCRX | 31% Poorly correlated | +0.50% | ||
TEVA - PCRX | 29% Poorly correlated | -0.99% | ||
BMCS - PCRX | 29% Poorly correlated | N/A | ||
NBIX - PCRX | 25% Poorly correlated | -1.18% | ||
ESPR - PCRX | 23% Poorly correlated | -8.23% | ||
More |
A.I.dvisor tells us that TEVA and ELAN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TEVA and ELAN's prices will move in lockstep.
Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
---|---|---|---|---|
TEVA | 100% | -0.99% | ||
ELAN - TEVA | 33% Poorly correlated | +0.50% | ||
PCRX - TEVA | 30% Poorly correlated | -2.08% | ||
PAHC - TEVA | 26% Poorly correlated | +0.84% | ||
VTRS - TEVA | 26% Poorly correlated | +0.54% | ||
LNTH - TEVA | 25% Poorly correlated | -6.33% | ||
More |